Champions Oncology (CSBR) Free Cash Flow Growth (3y) (2013 - 2026)
Champions Oncology (CSBR) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 21.16% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 45.09% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 80.69% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -23.92% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 8.92% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -4.45% |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | -15.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -15.50% |
| Jan 31, 2026 | -54.39% |
| Oct 31, 2025 | -38.34% |
| Jul 31, 2025 | 32.59% |
| Apr 30, 2025 | 187.72% |
| Jan 31, 2025 | -65.66% |
| Oct 31, 2024 | -36.97% |
| Jul 31, 2024 | 34.81% |
| Apr 30, 2024 | 13.83% |
| Jan 31, 2024 | 1.81% |
| Oct 31, 2023 | 10.99% |
| Jul 31, 2023 | -48.14% |
| Apr 30, 2023 | -50.76% |
| Jan 31, 2023 | 96.47% |
| Oct 31, 2022 | 65.94% |
| Jul 31, 2022 | 2.63% |
| Apr 30, 2022 | 37.73% |
| Jan 31, 2022 | 56.60% |
| Oct 31, 2021 | 72.55% |
| Jul 31, 2021 | -95.99% |